| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
21,110,000 |
| Market
Cap: |
5.48(M) |
| Last
Volume: |
4,769,812 |
Avg
Vol: |
4,756,792 |
| 52
Week Range: |
$0.2598 - $0.2598 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Plus Therapeutics is a clinical-stage pharmaceutical company focused on the development, manufacture and commercialization of treatments for patients battling cancer and other life-threatening diseases. The clinical stage drugs in Co.'s pipeline are: Rhenium NanoLiposomes, a radiotherapy for patients with recurrent glioblastoma; DocePLUS™, a chemotherapy for patients with tumors that has been evaluated in a completed U.S. single-center Phase 1 clinical trial; and DoxoPLUS™, a generic chemotherapy that has been evaluated in a completed, bioequivalence clinical trial in the U.S., Canada, and Ukraine versus Janssen's CAELYX® in patients with ovarian cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
48,285 |
48,285 |
100,872 |
108,373 |
| Total Buy Value |
$98,501 |
$98,501 |
$185,764 |
$199,106 |
| Total People Bought |
6 |
6 |
6 |
6 |
| Total Buy Transactions |
6 |
6 |
17 |
20 |
| Total Shares Sold |
0 |
0 |
2,068 |
3,568 |
| Total Sell Value |
$0 |
$0 |
$4,053 |
$4,525 |
| Total People Sold |
0 |
0 |
1 |
2 |
| Total Sell Transactions |
0 |
0 |
1 |
2 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Swissquote Bank Sa |
|
• • • |
2018-01-11 |
4 |
S |
$0.34 |
$24,716 |
D/D |
(72,630) |
5,328,229 |
|
- |
|
| Swissquote Bank Sa |
|
• • • |
2018-01-10 |
4 |
S |
$0.38 |
$6,007 |
D/D |
(15,796) |
5,400,859 |
|
- |
|
| Swissquote Bank Sa |
|
• • • |
2018-01-09 |
4 |
S |
$0.37 |
$38,332 |
D/D |
(100,000) |
5,416,655 |
|
- |
|
| Harris John David |
VP and GM Cell Therapy |
• – – |
2016-08-10 |
4 |
B |
$2.03 |
$5,075 |
D/D |
2,500 |
7,000 |
2.74 |
- |
|
| Lyons Gary A |
Director |
– • – |
2016-06-15 |
4 |
OE |
$0.00 |
$0 |
I/I |
1,900 |
4,358 |
|
- |
|
| Rickey David |
Director |
– • – |
2016-06-15 |
4 |
OE |
$0.00 |
$0 |
I/I |
22,000 |
71,226 |
|
- |
|
| Hawkins Richard J |
Director |
– • – |
2016-06-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,356 |
8,435 |
|
- |
|
| Kesten Steven |
Exec VP and Chief MO |
• – – |
2016-06-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
200 |
3,481 |
|
- |
|
| Girao Tiago |
VP & Chief Financial Officer |
• – – |
2016-06-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,667 |
14,084 |
|
- |
|
| Hayden Jeremy B. |
General Counsel & VP of BD |
• – – |
2016-06-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,896 |
3,643 |
|
- |
|
| Harris John David |
VP and GM Cell Therapy |
• – – |
2016-06-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,500 |
4,500 |
|
- |
|
| Hedrick Marc H |
President and CEO |
• • – |
2016-06-15 |
4 |
OE |
$0.00 |
$0 |
I/I |
41,305 |
44,292 |
|
- |
|
| Rickey David |
Director |
– • – |
2016-06-14 |
4 |
B |
$2.10 |
$10,500 |
I/I |
5,000 |
55,226 |
2.1 |
- |
|
| Naughton Gail K |
Director |
– • – |
2016-06-14 |
4 |
B |
$2.10 |
$2,100 |
D/D |
1,000 |
2,400 |
2.31 |
- |
|
| Harris John David |
VP and GM Cell Therapy |
• – – |
2016-05-13 |
4 |
B |
$2.71 |
$5,420 |
D/D |
2,000 |
2,000 |
2.74 |
- |
|
| Rickey David |
Director |
– • – |
2016-03-09 |
4 |
B |
$0.19 |
$28,290 |
I/I |
150,000 |
753,385 |
2.1 |
- |
|
| Girao Tiago |
VP & Chief Financial Officer |
• – – |
2016-01-28 |
4/A |
A |
$0.00 |
$0 |
D/D |
35,250 |
126,250 |
|
- |
|
| Kesten Steven |
Exec VP and Chief MO |
• – – |
2016-01-28 |
4 |
A |
$0.00 |
$0 |
D/D |
47,000 |
49,201 |
|
- |
|
| Girao Tiago |
VP & Chief Financial Officer |
• – – |
2016-01-28 |
4 |
A |
$0.00 |
$0 |
D/D |
35,250 |
123,250 |
|
- |
|
| Hedrick Marc H |
President and CEO |
• • – |
2016-01-28 |
4 |
A |
$0.00 |
$0 |
D/D |
70,500 |
575,111 |
|
- |
|
| Thompson Tommy G |
Director |
– • – |
2015-09-03 |
4 |
B |
$0.37 |
$9,531 |
I/I |
25,449 |
83,600 |
2.1 |
- |
|
| Hayden Jeremy B. |
General Counsel & VP of BD |
• – – |
2015-09-02 |
4 |
B |
$0.36 |
$2,911 |
D/D |
8,200 |
26,200 |
2.66 |
- |
|
| Rickey David |
Director |
– • – |
2015-08-28 |
4 |
B |
$0.31 |
$17,629 |
I/I |
56,000 |
653,385 |
2.1 |
- |
|
| Hedrick Marc H |
President and CEO |
• • – |
2015-08-28 |
4 |
B |
$0.31 |
$372 |
I/I |
1,200 |
44,800 |
2.58 |
- |
|
| Hedrick Marc H |
President and CEO |
• • – |
2015-08-27 |
4 |
B |
$0.31 |
$3,052 |
I/I |
10,000 |
43,600 |
2.58 |
- |
|
340 Records found
|
|
Page 3 of 14 |
|
|
